No Data
No Data
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies Remains a Buy on Amgen (AMGN)
Amgen Seeing Muted Upside Potential for Drug Pipeline, Truist Says
Amgen's stock price has dropped, analysts warn that the speculation on weight loss drugs has already been digested by the market.
Amgen Inc.'s stocks fell on Monday after an analyst no longer holds a bullish view on this biotechnology giant, citing concerns that investor optimism about a candidate obesity drug has been reflected in the stock price, with more downside risks than upside opportunities. Truist analyst Srikripa Devarakonda downgraded the stock from buy for the past 11 months to hold. However, she raised the target price from $320 to $333, but the new target price is only 1.4% higher than last Friday's closing price. The stock traded down 1.1% in pre-market trading, following a rise last Friday
Amgen Stock Falls. The Obesity Drug Landscape Is Getting Crowded.
Amgen Analyst Ratings
No Data
No Data
104476495 : h
章允量 :
affable Blobfish_403 : The economic recession is hard to conceal, but the economic data before the election shouldn't look too bad, right?! Data is often revised afterwards.
103677010 : noted
Ghost2737 affable Blobfish_403 : Data is fake
View more comments...